Helicobacter pylori infection. B98.0 Helicobacter pylori [H.pylori] as the cause of diseases classified to other chapters
Conditions
Interventions
Intervention 1: yomogi,250mg capsules contain dried yeast of saccharromyces boulardi,once daily,for one month. Intervention 2: placebo,250mg capsules contain lactose and starch powder,once daily,for o
Treatment - Drugs
Placebo
yomogi,250mg capsules contain dried yeast of saccharromyces boulardi,once daily,for one month
placebo,250mg capsules contain lactose and starch powder,once daily,for one month
Sponsors
Birjand University of Medical Science
Eligibility
Sex/Gender
All
Age
9 Years to 12 Years
Inclusion criteria
Inclusion criteria: inclusion criteria:9-12 year old children who study in Birjands grade schools exclusion criteria: dissatisfaction in cooperation;significant gastrointestinal sign and symptom;antibiotic usage in previous month;history of antiacid usage(PPI or H2 blocker);diarrhea at the time of sampling;history of any immunodeficiency;any kind of food and drug allergy; use of antibiotics for other diseases in time of intervention in case and control group
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| H.pylori stool antigen. Timepoint: before and at the end of intervention. Method of measurement: quantitative in microgram/ml. | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of diarrhea due to intervention. Timepoint: at the end of intervention. Method of measurement: questionnaire.;Incidence of improvement in weight gaining due to intervention. Timepoint: at the end of intervention. Method of measurement: questionnaire.;Incidence of improvement in bowel habit due to intervention. Timepoint: at the end of intervention. Method of measurement: questionnaire.;Incidence of vomitting due to intervention. Timepoint: at the end of interventin. Method of measurement: questionnaire.;Incidence of flatulence due to intervention. Timepoint: at the end of intervention. Method of measurement: questionnaire.;Incidence of fever due to intervention. Timepoint: at the end of intervention. Method of measurement: questionnaire.;Incidence of abdominal pain due to intervention. Timepoint: at the end of intervention. Method of measurement: questionnaire.;Incidence of other bad effects due to intervention. Timepoint: at the end of intervention. Method of measurement: questionnaire.;Incidence of improvement in appetite due to intervention. Timepoint: at the end of intervention. Method of measurement: questionnaire.;Incidence of other good effects due to intervention. Timepoint: at the end of intervention. Method of measurement: qustionnaire.;Incidence of nausea due to intervention. Timepoint: at the end of intervention. Method of measurement: questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFatemeh Basirinejad
Birjand University of Medical Science
Outcome results
None listed